Please note: The information displayed on this page might be outdated.
Kiadis Pharma N.V.: NK-cell platform administered as adjunct I-O on top of HSCT. High-dose potent NK cells expanded/activated w patented PM21 nanoparticles. Launched FIH POC trial in r/r AML patients (Feb 2020); set to launch additional HSCT trial later in 2020 w/interim data exp 2021. Presenting new data on ex-vivo FC21 expanded NK-cell therapy in 13 patients at EBMT in 2020. Established POC in 37 patients total.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe, US - New England
Clinical Stage
Phase III, Phase l or ll, Pre-Clinical Stage
Disease Space
Hematology, Immunotherapy, Oncology
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public
Market Cap
<100MM
Therapeutic Modalities
Cell Therapy
Website:
Address:
Boston
Boston, MA
United States

Company Participants at Solebury Trout KOL Day

  • Arthur Lahr, CEO

Top 10 Holders of Kiadis Pharma NV

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Empery Asset Management LP 6.60 1,950,779 0.00 Stakes 9/1/20
BNP Paribas Asset Management Belgium SA 0.40 116,931 0.00 Funds 7/31/20
FundQuest Advisor 0.11 41,691 0.00 Funds 9/30/19
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.